Pernix Therapeutics (PTX) Reports Q2 Loss of $0.47/Share
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Pernix Therapeutics (NASDAQ: PTX) reported Q2 EPS of ($0.47), versus ($0.62) reported last year. Revenue for the quarter came in at $36.75 million, versus $46.98 million reported last year.
For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald's (MCD) Tops Q4 EPS by 3c
- General Electric (GE) PT Lowered to $35 at UBS Following 4Q Report
- Expect Twilio (TWLO) To Exceed Baseline Revenue Estimates, 2017 Guidance Likely Conservative - William Blair
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!